Mirum Pharma rises as hepatitis delta drug hits main goal

Mirum Pharmaceuticals

27/04/2026 13:10

** Shares of biotech firm Mirum Pharmaceuticals MIRM.O rise 2% to $92.99 premarket

** Co says its experimental drug brelovitug met the main goal in a mid-stage study for chronic hepatitis delta, a severe liver infection that can quickly cause liver failure

** Says 100% of patients on the lower dose and 75% on the higher dose saw a sharp drop in virus levels after 24 weeks, versus none in the control group

** Says up to 45% of treated patients also saw liver enzymes return to normal, a sign of improved liver health

** Adds the drug was well tolerated, with few serious side effects

** Says expects late‑stage studies data in second half of 2026 and a possible U.S. launch in 2027

** As of last close, stock up ~16% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))